Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells

This study reports that B-chronic lymphocytic leukemia (B-
Toll-like receptors (TLRs) are major agents of innate immunity and initiators of adaptive immunity, involved in the activation of normal B-lymphocytes. TLRs are pattern recognition receptors (PRP) recognizing pathogens via pathogen-specific molecular patterns (PAMPs).
1 Although mRNAs derived from TLR genes have been reported in B-cells from lymphoproliferative disorders, 2 the expression and functionality of TLR proteins on these cells has seldom been investigated. However, such structures could provide an interesting therapeutic target if they are functional and their triggering induces relevant modifications of tumoral cells.
Such approaches could be proposed for second-line therapy in CLL patients who harbour minimal residual disease after achieving complete remission.
Using flow cytometry, we examined the expression of TLRs proteins in normal and CLL B-cells. We then evaluated the effect of TLRs ligands directed to two of the TLRs expressed on B-CLL cells in terms of costimulary immunophenotype, proliferation and apoptosis.
In Since imidazoquinolines have been described in the literature as TLR7 ligands, 3 the imidazoquinoline-like molecule, imiquimod R837 was used to engage TLR7 on B-CLL cells. This induced almost no variation in the expression of CD80, CD83, CD86, CD54 or CD58. By contrast, it induced a significantly increased expression of HLA-DR, and CD40 on all B-CLL cells in all patients ( Figure 1A) . Imiquimod R837 at 5 µg/mL or higher was concomitantly responsible for a rapid and major induction of apoptosis as shown by scatter changes of the cells in flow cytometry and as measured by the TUNEL method detecting endonucleases-related DNA breaks and repair by TdT. While spontaneous apoptosis was impaired by PMA and 2 µg/mL of imiquimod R837, apoptosis reached 70% by day 1 with the highest dose of imiquimod R837 and almost 100% on day 3 ( Figure  1B ). This is consistent with data reported by Spaner et al. 4 using another imidazoquinoline, S28690, at a lower concentration together with PMA. These authors observed a slightly higher expression of activation and costimulatory markers compared with our results. However, they reported that B-CLL cells treated with S28690 alone could not induce T-cell proliferation in an MLR assay. Interestingly, the lowest concentration of imiquimod R837 used here, which is nearest to that used by Spaner et al., 4 appeared to protect B-CLL cells from apoptosis, while the proapoptotic effect was observed from 5 µg/mL. These data suggest that imidazoquinolines, already used as topic in humans, 5 could be used as complementary chemotherapy for CLL clearance, as reported in lymphoma. 6, 7 TLR9 is a natural receptor for CpG of bacterial origin. Several synthetic oligonucleotides with CpG motifs have been reported to be efficient activators of cells displaying mRNA expression of TLR9. 8 The effect of B-CLL cells' TLR9 engagement was tested with a synthetic CpG-ODN M362 containing both A and B type immunostimulatory sequences. 9 CpG-ODN M362 induced a significant upregulation of the expression of all costimulatory molecules, and especially HLA-DR and CD40 (Figure 2A ). Opposite to imiquimod R837, CpG-ODN M352 was responsible for a significant decrease of spontaneous apoptosis whatever concentration was used ( Figure 2B ). These data are consistent with results reported for B-cells from healthy donors or from patients with B-cell malignancies 10 where B-CLL cells showed the strongest activation on stimulation from different CpG ODN, leading to B-CLL cell proliferation followed by apoptosis. The strong and fast induction of co-activation molecules that we observed could also enhance the antigen-presenting cell properties of CLL Bcells on ODN stimulation. This could lead to the generation of TH1 signals, as in normal B-cells. If this is the 
